Nosaka Kanae, Horie Yasushi, Shiomi Tatsushi, Itamochi Hiroaki, Oishi Tetsuro, Shimada Muneaki, Sato Shinya, Sakabe Tomohiko, Harada Tasuku, Umekita Yoshihisa
Division of Organ Pathology, Department of Pathology, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
†Department of Pathology, Tottori University Hospital, Yonago 683-8504, Japan.
Yonago Acta Med. 2015 Dec;58(4):151-6. Epub 2015 Dec 18.
Maspin is known to be a tumor suppressor protein and its prognostic significance in patients with several types of cancer has been reported. To date, however, no study has focused on the association between maspin expression and the prognosis of patients with adenocarcinoma of the uterine cervix. We explored the prognostic value of maspin expression with particular reference to its subcellular localization in patients with adenocarcinoma of the uterine cervix.
Paraffin-embedded tissue samples from 46 patients diagnosed as adenocarcinoma of the uterine cervix were immunohistochemically analyzed using an antibody for maspin. The patients were followed up for 3 to 165 months (median: 64.2 months) and the prognostic value was evaluated by the log-rank test and the Cox regression hazard model.
A sample was considered maspin-positive if maspin was expressed in only the cytoplasm; 69.6% (32 cases) of the specimens were maspin-positive, and there was significant correlation between positivity and recurrence (P = 0.022). Maspin-positive patients had both shorter disease free survival and shorter overall survival by the log-rank test (P = 0.023, P = 0.043, respectively). By Cox's multivariate analysis, the International Federation of Obstetrics and Gynecology (FIGO) status was the only independent prognostic factor for disease free survival and overall survival in patients with adenocarcinoma of the uterine cervix.
This is the first report to reveal an association between cytoplasmic maspin expression and the prognosis of patients with adenocarcinoma of the uterine cervix. Although further studies with a larger series of patients and a longer follow up period are necessary, the present results suggest that cytoplasmic maspin expression could be an indicator of unfavorable prognosis in patients with adenocarcinoma of the uterine cervix.
已知maspin是一种肿瘤抑制蛋白,已有报道称其在多种癌症患者中具有预后意义。然而,迄今为止,尚无研究聚焦于maspin表达与子宫颈腺癌患者预后之间的关联。我们探讨了maspin表达的预后价值,特别参考了其在子宫颈腺癌患者中的亚细胞定位。
对46例诊断为子宫颈腺癌患者的石蜡包埋组织样本,使用maspin抗体进行免疫组织化学分析。对患者进行3至165个月(中位数:64.2个月)的随访,并通过对数秩检验和Cox回归风险模型评估预后价值。
若maspin仅在细胞质中表达,则样本被视为maspin阳性;69.6%(32例)的标本为maspin阳性,且阳性与复发之间存在显著相关性(P = 0.022)。通过对数秩检验,maspin阳性患者的无病生存期和总生存期均较短(分别为P = 0.023,P = 0.043)。通过Cox多因素分析,国际妇产科联盟(FIGO)分期是子宫颈腺癌患者无病生存期和总生存期的唯一独立预后因素。
这是首份揭示细胞质maspin表达与子宫颈腺癌患者预后之间存在关联的报告。尽管需要对更多患者进行更大规模研究并进行更长时间随访,但目前结果表明,细胞质maspin表达可能是子宫颈腺癌患者预后不良的一个指标。